University of Missouri School of Medicine MU Health School of Medicine
News Divider

Compound improves cardiac function in mice with genetic heart defect


MU study recognized by American Heart Association

Congenital heart disease is the most common form of birth defect, affecting one out of every 125 babies, according to the National Institutes of Health. Researchers from the University of Missouri recently found success using a drug to treat laboratory mice with one form of congenital heart disease, hypertrophic cardiomyopathy — a weakening of the heart caused by abnormally thick muscle. By suppressing a faulty protein, the researchers reduced the thickness of the mice’s heart muscles and improved their cardiac functioning.

Maike Krenz, MD, has been studying hypertrophic cardiomyopathy for nearly 10 years, soon after a gene was discovered in 2001 that linked the disease to the genetic conditions Noonan syndrome and LEOPARD syndrome. In Noonan and LEOPARD syndromes, the thickened heart muscle of hypertrophic cardiomyopathy is caused by a defective Shp2 protein, created by a mutation in the gene PTPN11.

Krenz

“Previously, not much has been known about the biochemistry behind Shp2 and hypertrophic cardiomyopathy,” said Krenz, an assistant professor of medical pharmacology and physiology at the MU School of Medicine, and a researcher at MU’s Dalton Cardiovascular Research Center. “We know the thickened heart muscle is sick and doesn’t work properly, and we know a defective Shp2 protein can cause heart muscle to thicken. However, to create an effective treatment, we need to know what Shp2 is doing inside the heart to cause the defect.”

To test whether they could interrupt the heart’s hypersensitivity to growth signals, the researchers gave a chemical compound, PHPS1, to mice with a mutated gene that produces the defective Shp2 protein.

“Not only did the compound reduce the thickness of the heart muscle to the size of normal heart muscle, but it also improved the cardiac pumping of the heart,” Krenz said. “That’s important because people with hypertrophic cardiomyopathy have an increased risk of sudden cardiac death. If we could develop an effective treatment for the disease and improve patients’ heart function, we could save many people’s lives.”

Because of the role Shp2 plays in signaling heart growth, Krenz believes the research could be translated in the future into improved treatments for other types of heart disease, such as damage caused by heart attack.

Krenz presented the research findings, “Inhibition of Shp2’s Phosphatase Activity Ameliorates Cardiac Hypertrophy in LEOPARD Syndrome Models,” at the American Heart Association’s Scientific Sessions conference in November 2013, where it received the Outstanding Research Award in Pediatric Cardiology. LEOPARD syndrome is related to Noonan syndrome and receives its name from an acronym for multiple lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormal genitalia, retardation of growth and deafness.

Click here to download a high resolution portrait of Krenz.



MU Health Magazine

Divider

News and Events

White Coat Ceremony 2015 White Coat Ceremony Marks Start of Professional Journey for 104 Students
Students receive 'cloak of compassion' and pledge to uphold medicine's highest values

Eduardo Simoes, MD Tool Helps Public Health Agencies Prioritize Health Risks
Researcher works with Brazil to identify top risks for chronic diseases

Washington and Khosla U.S. South Asians More Reluctant to Seek Medication for Pain
Health care workers should be culturally aware when caring for patients, families

Segal Blood Vessels Can Actually Get Better With Age
Study finds that arteries adapt to oxidative stress caused by aging

Koopman Professor Awarded $2.2 Million Grant for Clear Blood Pressure Display
Goal is user-friendly information for better patient understanding

Scallan Impact of Type 2 Diabetes on Lymphatic Vessels Identified
Amino acid found in red meat, poultry may improve lymphatic function in diabetes

Springfield MU, CoxHealth, Mercy Address Critical Shortage of Physicians
Construction starts on new $42.5 million Patient-Centered Care Learning Center

Parrish Age-related self-destruction of cells makes kidney prone to injury
Researchers identify how the kidney cells’ self-destruct messages are spread

Staveley-O'Carroll Staveley-O’Carroll Named Surgery Chair, Cancer Center Director
Staveley-O’Carroll is accomplished physician-scientist

Mini Med High School Students get Hands-On Medical School Experience
MU School of Medicine hosts High School Mini Medical School

Cristo Rey MU Health System Partnership Promotes Diversity
Annual summit encourages students to try on health care careers

Hwang Key Component in Protein that Causes Cystic Fibrosis Identified
Findings may lay foundation for the development of medications

SOM Graduation 2015 MU School of Medicine to Award 101 Medical Degrees at Commencement
Forty-five will remain in Missouri for specialty training in residency




Media Relations
University of Missouri Health System
One Hospital Drive, DC028.00
Columbia, MO 65212
24/7 on-call pager: (573) 876-0708

Mary Jenkins
jenkinsmg@health.missouri.edu
(573) 882-7299

Jeff Hoelscher
hoelscherj@health.missouri.edu
(573) 884-1608

Derek Thompson
thompsonder@health.missouri.edu
(573) 882-3323

Diamond Dixon
DixonDi@health.missouri.edu
(573) 884-7541

Justin Kelley (Photographer)
kelleyju@health.missouri.edu
(573) 882-5786
Pager (573) 397-9289


Web Communications
University of Missouri Health System
One Hospital Drive, MA204G, DC018.00
Columbia, MO 65212
(573) 884-0298

Rich Gleba
glebar@health.missouri.edu
(573) 884-0298

Laura Gerding, APR
gerdingla@health.missouri.edu
(573) 882-9193

Velvet Hasner
hasnerv@health.missouri.edu
(573) 884-1115



Printer Friendly
Follow us on Twitter!   Facebook   YouTube Videos   Instagram   Pinterest  
Website created and maintained by the Office of Communications. Contact the MU School of Medicine.
Revised: February 04, 2014 - Copyright © 2014 - Curators of the University of Missouri. All rights reserved. DMCA and other copyright information. An equal opportunity/access/affirmative action/pro-disabled and veteran employer.